WallStSmart

Lexicon Pharmaceuticals Inc (LXRX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lexicon Pharmaceuticals Inc generates 9286% more annual revenue ($69.64M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -37.5%. LXRX earns a higher WallStSmart Score of 29/100 (F).

LXRX

Avoid

29

out of 100

Grade: F

Growth: 5.7Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -14.51

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LXRX2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
1572.0%10/10

Revenue surging 1572.0% year-over-year

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

LXRX4 concerns · Avg: 2.3/10
Market CapQuality
$835.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-12.9%2/10

ROE of -12.9% — below average capital efficiency

EPS GrowthGrowth
-63.4%2/10

Earnings declined 63.4%

Free Cash FlowQuality
$-14.73M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LXRX

The strongest argument for LXRX centers on Revenue Growth, Debt/Equity. Revenue growth of 1572.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : LXRX

The primary concerns for LXRX are Market Cap, Return on Equity, EPS Growth.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

LXRX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

LXRX is growing revenue faster at 1572.0% — sustainability is the question.

LXRX generates stronger free cash flow (-15M), providing more financial flexibility.

Bottom Line

LXRX scores higher overall (29/100 vs 24/100) and 1572.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lexicon Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?